

10/511438

705 Rec'd PCT/PTO 25 OCT 2004

Docket No. 260005US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Pascale GAILLARD, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/EP03/04323

GAU:

FILED: Herewith

EXAMINER:

FOR: PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Surinder Sachar

Richard L. Treanor

Registration No. 36,379

Surinder Sachar
Registration No. 34,423

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 260005US0PCT	SERIAL NO. New U.S. PCT Application Based on PCT/EP03/04323
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Pascale GAILLARD, et al.			
		FILING DATE Herewith	GROUP		
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AA	01/47920	07/05/01	WO	
	AB	02/26711	04/04/02	WO	
	AC	11-080155	03/26/99	JP(English abstract only)	
	AD				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)					
	AE	Roger J. DAVIS, "Signal transduction by the JNK group of MAP kinases", CELL, vol. 103, pages 239-252 10/13/00			
	AF	Shashi GUPTA, et al., "Selective interaction of JNK protein kinase isoforms with transcription factors", THE EMBO JOURNAL, vol. 15, no. 11, pages 2760-2770 1996			
	AG	Calin D. DUMITRU, et al., "TNF- α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway", CELL, vol. 103, pages 1071-1083 12/22/00			
	AH	Zuoning HAN, et al., "c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 108, no. 1, pages 73-81, 2001			
	AI	Hiroshi NISHINA, et al., "Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4(MKK4)-deficient T lymphocytes", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 6, pages 941-953 09/15/97			
	AJ	Stephan J. KEMPIAK, et al., "the jun kinase cascade is responsible for activating the CD28 response element of the IL-2 promoter: proof of cross-talk with the I κ B kinase cascade", THE JOURNAL OF IMMUNOLOGY, vol. 162, pages 3176-3187 1999			
	AK	S. M. de la MONTE, et al., "Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells", JOURNAL OF ALZHEIMER'S DISEASE, vol. 2, pages 261-281 2000			
	AL	Xiongwei ZHU, et al., "Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease", JOURNAL OF NEUROCHEMISTRY, vol. 76, pages 435-441 2001			
	AM	Li XU, et al., "Assess the in vivo activation of signal transduction pathways with pathdetect reporting systems", STRATEGIES, vol. 11, pages 94-97 2001			
	AN	Mausumee GUHA, et al., "LPS induction of gene expression in human monocytes", CELLULAR SIGNALLING, vol. 13, pages 85-94 2001			
	AO	A. Jackie Hunter, et al., "Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs", TIPS, vol. 16, pages 123-128 1995			
	AP	F. BLOCK, "Global ischemia and behavioural deficits", PROGRESS IN NEUROBIOLOGY, vol. 58, pages 279-295 1999			
	AQ	Susan C. GERHARDT, et al., "Motor activity changes following cerebral ischemia in gerbils are correlated with the degree of neuronal degeneration in hippocampus", BEHAVIORAL NEUROSCIENCE, vol. 102, no. 2, pages 301-303 1988			
	AR	A. Lorris BETZ, et al., "Blood-brain-cerebrospinal fluid barriers", BASIC NEUROCHEMISTRY: MOLECULAR, CELLULAR, AND MEDICAL ASPECTS, 5 th edition, chapter 32, pages 681-699, 1994			
	AS	Gary W. GOLDSTEIN, et al., "The blood-brain barrier", SCIENTIFIC AMERICAN, pages 70-79 September 1986			
	AT				
	AU			<input type="checkbox"/> Additional References sheet(s) attached	
Examiner				Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

New U.S. PCT Application Based on PCT/EP03/04323
Docket No.: 260005US0PCT

STATEMENT OF RELEVANCY

- 1) References AA-AC have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
- 2) References _____ have been cited in the corresponding _____ Search Report. A copy of these references is being submitted herewith.
- 3) References AE-AS are discussed in the specification. A copy of these references is being submitted here with.
- 4) References _____ are additional prior art known to Applicant. A copy of these references is being submitted herewith.